Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer

Shane M. Pearce, Shay Golan, Michael A. Gorin, Amy N. Luckenbaugh, Stephen B. Williams, John F. Ward, Jeffrey S. Montgomery, Khaled S. Hafez, Alon Z. Weizer, Phillip M. Pierorazio, Mohamad E. Allaf, Scott E. Eggener

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

Background Primary robot-assisted retroperitoneal lymph node dissection (R-RPLND) has been studied as an alternative to open RPLND in single-institution series for patients with low-stage nonseminomatous germ cell tumors (NSGCT). Objective To evaluate a multicenter series of primary R-RPLND for low-stage NSGCT. Design, setting, and participants Between 2011 and 2015, 47 patients underwent primary R-RPLND at four centers for Clinical Stage (CS) I-IIA NSGCT. Surgical procedure R-RPLND was performed using the da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA, USA). Outcome measurements and statistical analysis Data were collected regarding patient demographics, primary tumor characteristics, pathologic findings, and clinical outcomes. Results and limitations Forty-two patients (89%) were CS I and five (11%) were CS IIA. The median operative time was 235 min (interquartile range [IQR]: 214–258 min), estimated blood loss was 50 ml (IQR: 50–100 ml), node count was 26 (IQR: 18–32), and length of stay was 1 d. There were two intraoperative complications (4%), four early postoperative complications (9%), no late complications, and the rate of antegrade ejaculation was 100%. Of the eight patients (17%) with positive nodes (seven pN1and one pN2), five (62%) received adjuvant chemotherapy. The one recurrence was out of template in the pelvis after adjuvant chemotherapy (resected teratoma). The median follow-up was 16 mo and the 2-yr recurrence-free survival rate was 97% (95% confidence interval: 82–100%). Limitations include retrospective design and limited follow-up. Conclusions Our multicenter experience supports R-RPLND as a potential option at experienced centers in select patients with low-stage NSGCT. Informal comparison to open and laparoscopic series suggests R-RPLND has an acceptably low morbidity profile, but oncologic efficacy evaluation requires further evaluation. Patient summary We examined outcomes after robot-assisted retroperitoneal lymph node dissection for patients with low-stage nonseminomatous testicular cancer with our data suggesting the robotic approach has acceptable morbidity and early oncologic outcomes.

Original languageEnglish (US)
Pages (from-to)476-482
Number of pages7
JournalEuropean Urology
Volume71
Issue number3
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Keywords

  • Complications
  • Lymph node excision
  • Nonseminomatous germ cell tumor
  • Testicular neoplasms
  • Treatment outcome

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer'. Together they form a unique fingerprint.

Cite this